That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19

Matthew R Davis; Erin K McCreary; Jason M Pogue

doi:10.1007/s40121-020-00318-1

That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19

Infect Dis Ther. 2020 Sep;9(3):525-536. doi: 10.1007/s40121-020-00318-1. Epub 2020 Jul 10.

Authors

Matthew R Davis¹, Erin K McCreary², Jason M Pogue³

Affiliations

¹ Department of Clinical Pharmacy, University of California Los Angeles Ronald Reagan Medical Center, Los Angeles, CA, USA. MRDavis@mednet.ucla.edu.
² Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
³ Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

Abstract

Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.

Keywords: ACTT-1; Antiviral; COVID-19; Coronavirus disease 2019; Remdesivir; SARS-CoV-2.

Publication types

Review